Lopid Patent Term Restoration and Fairness Act of 1987: Hearing Before the Subcommittee on Courts, Civil Liberties, and the Administration of Justice of the Committee on the Judiciary, House of Representatives, One Hundredth Congress, First Session, October 8, 1987, Volume 4
United States. Congress. House. Committee on the Judiciary. Subcommittee on Courts, Civil Liberties, and the Administration of Justice
U.S. Government Printing Office, 1988 - 350 pages
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
acid activity additional Administration agents American application approval associated bill blood cent Chairman changes claim clinical clofibrate Committee compared concentrations Congress coronary heart disease deaths decreased determination diabetic diet drug effect elevated et al exclusivity extension fact factors fibre findings five Further gemfibrozil gemfibrozil treatment glucose HDL-cholesterol Health Helsinki Heart Study incidence increase indication initial Journal KASTENMEIER legislation levels limited lipase lipid lipoprotein long-term Lopid lowering mean method mmol/l months mortality myocardial infarction observed patent term patients period Phase IV study placebo plasma prevention primary prevention progression protection question ratio reason reduction reported Research risk Royal Society safety serum Services showed significant Society of Medicine subjects Table Thank total cholesterol treatment trial triglycerides Type values VLDL Warner-Lambert weeks
Page 113 - A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity, J.
Page 295 - Kagan A.: Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men.
Page 73 - I am a partner in the Washington, DC law firm of Covington & Burling. I have been asked to present testimony on patent term restoration.
Page 345 - Five-year findings of the Hypertension Detection and Followup Program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension.
Page 248 - For the purposes of paragraph (2)(B), the term "due diligence" means that degree of attention, continuous directed effort, and timeliness as may reasonably be expected from, and are ordinarily exercised by, a person during a regulatory review period.
Page 67 - HL-07182 from the National Heart, Lung and Blood Institute of the National Institutes of Health, and by the American Heart Association, Indiana Affiliate, Inc.